您的购物车当前为空
AGPAT4-IN-1 (Compound CL26) 是一种IC50为795 nM的共价AGPAT4抑制剂。该化合物通过与AGPAT4的Cys228位点形成共价结合,显著抑制acyltransferase活性及LPA到PA的转化,并影响下游mTOR/S6K通路。AGPAT4-IN-1 可提高肝细胞癌 (HCC) 对Sorafenib的敏感性,并通过协同反应诱导细胞凋亡 (apoptosis)。此外,AGPAT4-IN-1 显示出抗肿瘤活性,并在肝细胞癌异种移植小鼠模型中降低了致瘤性和干细胞特性。
AGPAT4-IN-1 (Compound CL26) 是一种IC50为795 nM的共价AGPAT4抑制剂。该化合物通过与AGPAT4的Cys228位点形成共价结合,显著抑制acyltransferase活性及LPA到PA的转化,并影响下游mTOR/S6K通路。AGPAT4-IN-1 可提高肝细胞癌 (HCC) 对Sorafenib的敏感性,并通过协同反应诱导细胞凋亡 (apoptosis)。此外,AGPAT4-IN-1 显示出抗肿瘤活性,并在肝细胞癌异种移植小鼠模型中降低了致瘤性和干细胞特性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | AGPAT4-IN-1 (Compound CL26) is a covalent AGPAT4 inhibitor with an IC50 of 795 nM. It binds covalently to the Cys228 site of AGPAT4, significantly inhibiting acyltransferase activity, the conversion of LPA to PA, and the downstream mTOR/S6K pathway. AGPAT4-IN-1 enhances the sensitivity of hepatocellular carcinoma (HCC) tumors to Sorafenib and significantly induces apoptosis through synergistic effects. This compound exhibits antitumor activity and reduces tumorigenicity and stem cell characteristics in a hepatocellular carcinoma xenograft mouse model. |
| 分子量 | 306.76 |
| 分子式 | C14H11ClN2O2S |
| CAS No. | 2411250-59-2 |
| Smiles | O=C(NCC=1OC(=CC1)C2=NC=3C=CC=CC3S2)CCl |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多